CagriSema

CagriSema: Investigational Semaglutide and Cagrilintide Combination

CagriSema is an investigational once-weekly injectable medicine being developed by Novo Nordisk for potential use in adults with overweight or obesity and adults with type 2 diabetes. It combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analogue.

Important UK status: CagriSema is not currently an authorised medicine for routine prescribing in the UK. It remains under clinical development and should not be presented as an approved weight-loss or diabetes treatment available for ordinary purchase. ClinicalTrials.gov currently describes CagriSema as an investigational medicine that doctors cannot yet prescribe.

What Is CagriSema?

CagriSema is a fixed-dose combination of cagrilintide and semaglutide designed to provide the effects of two complementary mechanisms in one once-weekly treatment. Novo Nordisk describes the current investigational combination as cagrilintide 2.4 mg plus semaglutide 2.4 mg.

Semaglutide works through the GLP-1 receptor pathway, while cagrilintide is an amylin analogue. Both mechanisms are being investigated for their effects on appetite, food intake and metabolic health.

The combination is being studied because researchers are evaluating whether targeting these pathways together can provide meaningful reductions in body weight and improvements in metabolic measures.

How Does CagriSema Work?

CagriSema combines two different types of activity:

• Semaglutide: a GLP-1 receptor agonist that influences appetite, food intake and glucose regulation.
• Cagrilintide: a long-acting amylin analogue being investigated for effects on appetite and satiety.

By combining these mechanisms, CagriSema is being studied as a potential treatment for obesity and type 2 diabetes. However, because development is ongoing, its final approved indications, dosing instructions, contraindications and prescribing requirements cannot be assumed until regulatory authorities have reviewed the medicine.

CagriSema and Weight Management

CagriSema is being investigated extensively for weight management in adults with overweight or obesity. ClinicalTrials.gov records phase 3 studies evaluating the combination in people with excess body weight.

In the REDEFINE 4 phase 3 study, Novo Nordisk reported that participants receiving the 2.4 mg/2.4 mg combination achieved 23.0% weight loss after 84 weeks when evaluated under the trial’s adherence-based analysis. However, the study did not meet its primary endpoint for demonstrating non-inferiority compared with tirzepatide 15 mg.

These results are research findings and should not be interpreted as a guarantee of weight loss for an individual. CagriSema remains investigational.

CagriSema and Type 2 Diabetes

CagriSema is also being studied in adults with type 2 diabetes. The REIMAGINE clinical development programme includes phase 3 studies evaluating blood glucose control and body weight.

Novo Nordisk reported phase 3 results from REIMAGINE 1–3 in 2026, with studies evaluating CagriSema across different groups of adults with type 2 diabetes. The company continues to develop the medicine and assess its potential regulatory pathway.

Clinical Research and Development

CagriSema has progressed through several stages of clinical research. Current phase 3 programmes include studies in obesity and type 2 diabetes.

ClinicalTrials.gov lists phase 3 research evaluating CagriSema against placebo and other established treatments. One phase 3 study in people with excess body weight enrolled 300 participants, while another study comparing CagriSema with tirzepatide in people with type 2 diabetes enrolled more than 1,000 participants.

Because these are clinical research programmes, trial results should be considered alongside the study design, endpoints, population and regulatory assessment rather than treated as evidence that the medicine is already approved.

CagriSema Compared With Semaglutide

Semaglutide is already used in several authorised medicines, including Ozempic and Rybelsus. CagriSema is different because it combines semaglutide with cagrilintide.

For information about authorised semaglutide medicines, see our diabetes medicines category and related medicine information on our health and medicine blog.

CagriSema Compared With Tirzepatide

Tirzepatide is another medicine that acts through two hormonal pathways and is available in the UK under the Mounjaro brand for authorised indications. You can read more about Mounjaro (tirzepatide).

CagriSema and tirzepatide are not the same medicine. CagriSema combines an amylin analogue with a GLP-1 receptor agonist, whereas tirzepatide acts as a GIP and GLP-1 receptor agonist.

Is CagriSema Available in the UK?

CagriSema is not currently authorised for routine prescribing in the UK. It remains an investigational medicine undergoing clinical development.

This distinction is important when researching products promoted online as “CagriSema”. An investigational medicine should not be confused with an authorised prescription medicine. Products marketed as CagriSema outside legitimate clinical research may not contain the expected ingredients, strength or quality.

For current UK regulatory information, consult the Medicines and Healthcare products Regulatory Agency (MHRA).

CagriSema Safety and Side Effects

Because CagriSema is still under investigation, its final UK prescribing information and complete safety profile have not been established in the way they are for authorised medicines.

Clinical research has reported gastrointestinal adverse events among participants. Novo Nordisk reported that gastrointestinal adverse events were the most common adverse events in REDEFINE 4 and were generally mild to moderate in that study.

People should not self-administer investigational CagriSema or obtain unverified products marketed online. Anyone considering weight-management treatment should discuss authorised options with an appropriately qualified healthcare professional.

Why CagriSema Is Being Studied

Obesity and type 2 diabetes are complex metabolic conditions, and researchers continue to investigate medicines that can target appetite, food intake, blood glucose and body weight through different biological pathways.

The combination of semaglutide and cagrilintide is intended to investigate whether GLP-1 and amylin-based mechanisms can complement each other. CagriSema therefore represents an important area of ongoing metabolic medicine research, but its future clinical role depends on further evidence and regulatory review.

Important Information Before Considering CagriSema

• CagriSema is investigational and is not currently authorised for routine prescribing in the UK.
• It should not be treated as an approved replacement for Wegovy, Mounjaro, Ozempic or other authorised medicines.
• Do not purchase or use unverified products claiming to contain CagriSema.
• Clinical trial results do not guarantee individual treatment outcomes.
• Future approved doses and indications may differ from doses investigated in clinical trials.
• Always obtain medical advice before starting prescription weight-management or diabetes treatment.

Frequently Asked Questions

What is CagriSema?

CagriSema is an investigational fixed-dose combination of cagrilintide and semaglutide being developed by Novo Nordisk for potential use in obesity and type 2 diabetes.

Is CagriSema approved in the UK?

No. CagriSema is currently an investigational medicine and is not authorised for routine prescribing in the UK.

Can doctors prescribe CagriSema?

ClinicalTrials.gov currently states that CagriSema cannot yet be prescribed by doctors because it remains an investigational medicine.

Does CagriSema contain semaglutide?

Yes. The investigational fixed-dose combination contains semaglutide together with cagrilintide.

Is CagriSema the same as Ozempic?

No. Ozempic contains semaglutide, while CagriSema combines semaglutide with cagrilintide.

Is CagriSema the same as Mounjaro?

No. Mounjaro contains tirzepatide, which acts on GIP and GLP-1 receptors. CagriSema combines cagrilintide with semaglutide.

Is CagriSema available for weight loss?

CagriSema is being investigated for weight management, but it is not currently an authorised routine treatment in the UK.

Where can I find reliable information about CagriSema?

Reliable information can be found through ClinicalTrials.gov, the MHRA and official research updates from Novo Nordisk.

Key Product Information

Product	CagriSema
Active components	Cagrilintide + semaglutide
Drug type	Investigational fixed-dose combination
Administration studied	Once-weekly subcutaneous injection
Research areas	Obesity, overweight and type 2 diabetes
Developer	Novo Nordisk
UK routine prescribing	Not currently authorised
Purchase status	Not available as an authorised routine prescription product

Authoritative Resources

ClinicalTrials.gov – CagriSema obesity clinical trial

ClinicalTrials.gov – CagriSema type 2 diabetes clinical trial

UK Medicines and Healthcare products Regulatory Agency (MHRA)

Novo Nordisk – CagriSema REDEFINE 4 results

Related Medicines

For currently authorised medicines and treatment information, explore Ozempic (semaglutide), Rybelsus (semaglutide), Mounjaro (tirzepatide), our weight-management medicines or our health and medicine blog.

Medical disclaimer: This page is for educational and informational purposes. CagriSema remains an investigational medicine and should not be used outside an appropriate clinical research or authorised regulatory setting. Always follow advice from a qualified healthcare professional.